Altimmune (ALT) Market Analysis: Reddit Discussion & Catalyst Evaluation

: Reddit Discussion (Nov 23,2025 EST)
: Nov29,2025

---

A Reddit discussion evaluated Altimmune (ALT) with three perspectives:

• Bullish
  : Undervalued ($<5), upcoming catalysts (48-week IMPACT trial data, FDA End of Phase2 meeting), and ~21% short interest as potential price drivers.
• Bearish
  : Valuation vs. acquired peers is premature without full 48-week data; past biotech losses cited.
• Neutral
  : Strong transparency via Lancet publication of Phase2b data (180-page supplement).

---

ALT trades at

(+1.74% daily gain) with below-average volume (1.54M vs.2.83M avg) [0], indicating limited immediate Reddit discussion impact.

Key events to watch:

• Dec3,2025: Piper Sandler Healthcare Conference fireside chat [1]
• Q42025: Final48-week IMPACT trial data [1]
• TBD: FDA End of Phase2 meeting for pemvidutide

High short interest (~22.3% as of Nov14,2025) [3] creates dual risk/reward: positive news may trigger a squeeze; negative data could amplify declines.

---

##3. Key Data Extraction

Metric	Value	Source
Current Price	$5.26	[0]
Market Cap	$464.23M	[0]
Short Interest	~22.3% (23.29M shares)	[3]
Phase2b MASH Resolution	52-58% vs placebo’s20%	[1]
Phase2b Fibrosis Improvement	No significant gain vs placebo	[1]
Peer Acquisition Valuations	Novo/Akero ($4.7B), RHHBY/89bio ($3.5B), Pfizer/Metsera ($7.3B)	[4]
Operating Cash Flow (TTM)	-$66.35M	[3]

---

##4. Affected Instruments

• Altimmune (ALT)

• Biotech (MASH/obesity/GLP-1 therapy subsector)

• Acquired peers: Akero (Novo),89bio (RHHBY), Metsera (Pfizer) [4]

---

##5. Context for Decision-Makers

• Exact timeline for 48-week data/FDA meeting
• Pemvidutide’s competitive positioning vs FGF21 analogs
• Long-term cash runway sustainability ($211M short-term investments [3])

• Bullish
  : Catalysts + short interest = potential rapid appreciation
• Bearish
  : Data gaps & unproven efficacy limit valuation comparability
• Neutral
  : Lancet publication demonstrates rigor but doesn’t address bearish concerns

---

##6. Risk Considerations & Monitoring

• Clinical
  : Unproven fibrosis efficacy (24-week data showed no gain [1])
• Volatility
  : High short interest amplifies price swings [3]
• Financial
  : Negative EPS (-$1.07) & operating cash flow (-$66.35M) [0,3]

1.48-week IMPACT trial data (fibrosis improvement/safety)
2.FDA meeting outcome (Phase3 guidance)
3.Strategic partnerships (similar to peer acquisitions [4])
4.Short interest trends

---

Disclaimer

: This report is informational only—does not constitute investment advice. Biotech stocks are high-risk; conduct independent research.

Risk Warning

: ALT’s high short interest & clinical data gaps may lead to significant volatility.